Universitätsklinikum Gießen und Marburg (UKGM)

Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds (2019) Boeder NF, Weissner M, Blachutzik F, Ullrich H, Anadol R, Tröbs M, Muenzel T, et al. Journal article Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study (2019) Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, et al. Journal article Addiction in IBD patients: more than just smoke? (2019) Hirschmann S, Koehnen J, Schuster B, Atreya R, Krauss N, Mudter J, Dauer M, et al. Conference contribution Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD (2019) Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, et al. Journal article Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - The study design of the LIBERAL-Trial (2019) Meybohm P, Lindau S, Treskatsch S, Francis RCE, Spies C, Velten M, Wittmann M, et al. Journal article Geriatric Trauma Center DGU®: Evaluation of clinical and economic parameters: A pilot study in a german university hospital AltersTraumaZentrum DGU®: Evaluation klinischer und ökonomischer Parameter: Eine Pilotstudie an einer deutschen Universitätsklinik (2019) Knobe M, Boettcher B, Coburn M, Friess T, Bollheimer LC, Werner CJ, Bach JP, et al. Journal article Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation (2019) Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, et al. Journal article Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, et al. Conference contribution Comparison of leukemia-associated immunophenotype (LAIP)-based and different-from-normal (DfN)-based analysis of measurable residual disease (MRD) in patients with AML (2019) Von Bonin M, Buecklein V, Krause S, Voelkl S, Rieger M, Berg T, Brendel C, et al. Conference contribution Impact of comorbidities on outcome with second and further line TKI treatment in patients with chronic myeloid leukemia (2019) Yildirim-Zuemruet G, Kohlbrenner K, Hehlmann R, Fabarius A, Baerlocher GM, Krause S, Burchert A, et al. Conference contribution